HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 231 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.38 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $65,000 | +14.0% | 3,672 | -3.6% | 0.00% | – |
| Q3 2019 | $57,000 | -16.2% | 3,808 | -3.1% | 0.00% | -100.0% |
| Q2 2019 | $68,000 | +9.7% | 3,929 | +0.9% | 0.00% | 0.0% |
| Q1 2019 | $62,000 | -3.1% | 3,895 | -10.9% | 0.00% | 0.0% |
| Q4 2018 | $64,000 | -22.0% | 4,373 | -2.5% | 0.00% | 0.0% |
| Q3 2018 | $82,000 | +57.7% | 4,484 | +48.0% | 0.00% | 0.0% |
| Q2 2018 | $52,000 | -17.5% | 3,029 | -4.8% | 0.00% | 0.0% |
| Q1 2018 | $63,000 | +28.6% | 3,181 | +30.9% | 0.00% | 0.0% |
| Q4 2017 | $49,000 | +69.0% | 2,430 | +40.5% | 0.00% | – |
| Q3 2017 | $29,000 | +38.1% | 1,730 | +3.4% | 0.00% | – |
| Q2 2017 | $21,000 | +10.5% | 1,673 | +15.9% | 0.00% | – |
| Q1 2017 | $19,000 | +90.0% | 1,444 | +36.0% | 0.00% | – |
| Q4 2016 | $10,000 | -73.0% | 1,062 | -65.3% | 0.00% | -100.0% |
| Q3 2016 | $37,000 | +42.3% | 3,062 | -0.0% | 0.00% | 0.0% |
| Q2 2016 | $26,000 | – | 3,063 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |